Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MaiLi is a portfolio of premium hyaluronic acid (HA) dermal fillers developed by Sinclair Pharma (a subsidiary of Huadong Medicine). The product line includes four variants—Precise, Define, Volume, and Extreme—each designed with specific HA concentrations and rheological properties for applications ranging from fine line correction to deep facial volume restoration. Utilizing proprietary OxiFree™ technology and Smart Spring Science, the fillers create a supple, spring-like gel that integrates into the dermis to provide natural-looking results and maintain facial expression. All formulations include 0.3% lidocaine to enhance patient comfort during the injection process. MaiLi is CE-marked for the treatment of facial wrinkles, lip enhancement, volume restoration, and HIV-related lipoatrophy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MaiLi.